Literature DB >> 26866725

β-Globin-Expressing Definitive Erythroid Progenitor Cells Generated from Embryonic and Induced Pluripotent Stem Cell-Derived Sacs.

Atsushi Fujita1, Naoya Uchida1, Juan J Haro-Mora1, Thomas Winkler2, John Tisdale1.   

Abstract

Human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells represent a potential alternative source for red blood cell transfusion. However, when using traditional methods with embryoid bodies, ES cell-derived erythroid cells predominantly express embryonic type ɛ-globin, with lesser fetal type γ-globin and very little adult type β-globin. Furthermore, no β-globin expression is detected in iPS cell-derived erythroid cells. ES cell-derived sacs (ES sacs) have been recently used to generate functional platelets. Due to its unique structure, we hypothesized that ES sacs serve as hemangioblast-like progenitors capable to generate definitive erythroid cells that express β-globin. With our ES sac-derived erythroid differentiation protocol, we obtained ∼120 erythroid cells per single ES cell. Both primitive (ɛ-globin expressing) and definitive (γ- and β-globin expressing) erythroid cells were generated from not only ES cells but also iPS cells. Primitive erythropoiesis is gradually switched to definitive erythropoiesis during prolonged ES sac maturation, concurrent with the emergence of hematopoietic progenitor cells. Primitive and definitive erythroid progenitor cells were selected on the basis of glycophorin A or CD34 expression from cells within the ES sacs before erythroid differentiation. This selection and differentiation strategy represents an important step toward the development of in vitro erythroid cell production systems from pluripotent stem cells. Further optimization to improve expansion should be required for clinical application. Stem Cells 2016;34:1541-1552.
© 2016 AlphaMed Press.

Entities:  

Keywords:  Erythroid differentiation; Globin expression; Pluripotent stem cells; Primitive and definitive hematopoiesis

Mesh:

Substances:

Year:  2016        PMID: 26866725      PMCID: PMC4892957          DOI: 10.1002/stem.2335

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  37 in total

1.  In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos.

Authors:  S I Nishikawa; S Nishikawa; H Kawamoto; H Yoshida; M Kizumoto; H Kataoka; Y Katsura
Journal:  Immunity       Date:  1998-06       Impact factor: 31.745

2.  Generation of red blood cells from human induced pluripotent stem cells.

Authors:  Jessica Dias; Marina Gumenyuk; HyunJun Kang; Maxim Vodyanik; Junying Yu; James A Thomson; Igor I Slukvin
Journal:  Stem Cells Dev       Date:  2011-05-11       Impact factor: 3.272

3.  Definitive hematopoiesis is autonomously initiated by the AGM region.

Authors:  A Medvinsky; E Dzierzak
Journal:  Cell       Date:  1996-09-20       Impact factor: 41.582

4.  Ontogeny of the haemopoietic system: yolk sac origin of in vivo and in vitro colony forming cells in the developing mouse embryo.

Authors:  M A Moore; D Metcalf
Journal:  Br J Haematol       Date:  1970-03       Impact factor: 6.998

5.  Differential expression of KDR/VEGFR-2 and CD34 during mesoderm development of the early human embryo.

Authors:  F Cortés; C Debacker; B Péault; M C Labastie
Journal:  Mech Dev       Date:  1999-05       Impact factor: 1.882

6.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

7.  Developmental and species-divergent globin switching are driven by BCL11A.

Authors:  Vijay G Sankaran; Jian Xu; Tobias Ragoczy; Gregory C Ippolito; Carl R Walkley; Shanna D Maika; Yuko Fujiwara; Masafumi Ito; Mark Groudine; M A Bender; Philip W Tucker; Stuart H Orkin
Journal:  Nature       Date:  2009-08-05       Impact factor: 49.962

8.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.

Authors:  Bin-Kuan Chou; Prashant Mali; Xiaosong Huang; Zhaohui Ye; Sarah N Dowey; Linda Ms Resar; Chunlin Zou; Y Alex Zhang; Jay Tong; Linzhao Cheng
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

9.  Highly potent human hematopoietic stem cells first emerge in the intraembryonic aorta-gonad-mesonephros region.

Authors:  Andrejs Ivanovs; Stanislav Rybtsov; Lindsey Welch; Richard A Anderson; Marc L Turner; Alexander Medvinsky
Journal:  J Exp Med       Date:  2011-10-31       Impact factor: 14.307

10.  A Quantitative Proteomic Analysis of Hemogenic Endothelium Reveals Differential Regulation of Hematopoiesis by SOX17.

Authors:  Raedun L Clarke; Aaron M Robitaille; Randall T Moon; Gordon Keller
Journal:  Stem Cell Reports       Date:  2015-08-11       Impact factor: 7.765

View more
  17 in total

1.  RNA Trans-Splicing Targeting Endogenous β-Globin Pre-Messenger RNA in Human Erythroid Cells.

Authors:  Naoya Uchida; Kareem N Washington; Brian Mozer; Charlotte Platner; Josiah Ballantine; Luke P Skala; Lydia Raines; Anna Shvygin; Matthew M Hsieh; Lloyd G Mitchell; John F Tisdale
Journal:  Hum Gene Ther Methods       Date:  2017-02-14       Impact factor: 2.396

2.  Induced pluripotent stem cell-based mapping of β-globin expression throughout human erythropoietic development.

Authors:  Kim Vanuytsel; Taylor Matte; Amy Leung; Zaw Htut Naing; Tasha Morrison; David H K Chui; Martin H Steinberg; George J Murphy
Journal:  Blood Adv       Date:  2018-08-14

3.  Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients.

Authors:  Naoya Uchida; Atsushi Fujita; Matthew M Hsieh; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale
Journal:  Hum Gene Ther Clin Dev       Date:  2017-04-17       Impact factor: 5.032

4.  Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells from Patients with Sickle Cell Disease.

Authors:  Naoya Uchida; Juan J Haro-Mora; Atsushi Fujita; Duck-Yeon Lee; Thomas Winkler; Matthew M Hsieh; John F Tisdale
Journal:  Stem Cells       Date:  2016-10-26       Impact factor: 6.277

5.  The Stagnant Adaptation of Defined and Xeno-Free Culture of iPSCs in Academia.

Authors:  Joseph T Vecchi; Tetsuro Wakatsuki
Journal:  Arch Stem Cell Res       Date:  2016-11-08

Review 6.  Stem cells and lung regeneration.

Authors:  Kalpaj R Parekh; Janna Nawroth; Albert Pai; Shana M Busch; Christiana N Senger; Amy L Ryan
Journal:  Am J Physiol Cell Physiol       Date:  2020-08-12       Impact factor: 4.249

7.  Enhanced Ex Vivo Generation of Erythroid Cells from Human Induced Pluripotent Stem Cells in a Simplified Cell Culture System with Low Cytokine Support.

Authors:  Claudia Bernecker; Mania Ackermann; Nico Lachmann; Lisa Rohrhofer; Holm Zaehres; Marcos J Araúzo-Bravo; Emile van den Akker; Peter Schlenke; Isabel Dorn
Journal:  Stem Cells Dev       Date:  2019-11-19       Impact factor: 3.272

8.  Biallelic correction of sickle cell disease-derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serum-free iPS-sac/erythroid differentiation.

Authors:  Juan J Haro-Mora; Naoya Uchida; Selami Demirci; Qi Wang; Jizhong Zou; John F Tisdale
Journal:  Stem Cells Transl Med       Date:  2020-02-07       Impact factor: 6.940

9.  The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors.

Authors:  Rachel Bayley; Forhad Ahmed; Katie Glen; Mark McCall; Adrian Stacey; Robert Thomas
Journal:  J Tissue Eng Regen Med       Date:  2017-04-03       Impact factor: 3.963

10.  Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production.

Authors:  Naoya Uchida; Selami Demirci; Juan J Haro-Mora; Atsushi Fujita; Lydia N Raines; Matthew M Hsieh; John F Tisdale
Journal:  Mol Ther Methods Clin Dev       Date:  2018-03-22       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.